CG ONCOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.71 USD | +9.07% |
|
+9.11% | 0.00% |
| 05-24 | Sector Update: Health Care Stocks Softer in Friday Afternoon Trading | MT |
| 05-24 | CG Oncology Shares Jump After Potential Combination Therapy for Bladder Cancer Meets Phase 2 Primary Endpoint | MT |
Valuation
| Fiscal Period: December | 2024 | 2025 | 2026 |
|---|---|---|---|
| Capitalization 1 | 2,180 | - | - |
| Enterprise Value (EV) 1 | 2,063 | 2,046 | 1,932 |
| P/E ratio | -19.2 x | -16.2 x | -23.4 x |
| Yield | - | - | - |
| Capitalization / Revenue | 1,312 x | 248 x | 22.8 x |
| EV / Revenue | 1,242 x | 233 x | 20.2 x |
| EV / EBITDA | -21.6 x | -19.1 x | -38.2 x |
| EV / FCF | -19.2 x | -14.2 x | -13.5 x |
| FCF Yield | -5.19% | -7.04% | -7.39% |
| Price to Book | 10.1 x | 17.4 x | 18 x |
| Nbr of stocks (in thousands) | 66,640 | - | - |
| Reference price 2 | 32.71 | 32.71 | 32.71 |
| Announcement Date | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 1.661 | 8.779 | 95.4 |
| EBITDA 1 | - | -55.43 | -95.42 | -107 | -50.56 |
| EBIT 1 | - | -55.45 | -100.5 | -123.4 | -95.65 |
| Operating Margin | - | - | -6,047.05% | -1,406.2% | -100.26% |
| Earnings before Tax (EBT) 1 | - | -48.61 | -96.19 | -121.6 | -98.52 |
| Net income 1 | -35.44 | -48.61 | -88.31 | -111.9 | -84.39 |
| Net margin | - | - | -5,315.93% | -1,274.18% | -88.45% |
| EPS 2 | -11.73 | -15.65 | -1.705 | -2.022 | -1.400 |
| Free Cash Flow 1 | - | -45.68 | -107.2 | -143.9 | -142.7 |
| FCF margin | - | - | -6,450.26% | -1,639.59% | -149.6% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 27/10/23 | 26/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.529 | 0.1763 | 0.1763 | 0.1763 | 0.1763 | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | -18.93 | -22.47 | -22.79 | -25.75 | -27.44 | -29.65 | - |
| Operating Margin | - | -4,247.45% | -12,923.78% | -14,601.88% | -15,560.03% | -16,815.06% | - |
| Earnings before Tax (EBT) 1 | - | -16.93 | -24.9 | -27.1 | -29.5 | - | - |
| Net income 1 | - | -16.93 | -24.9 | -27.1 | -29.5 | - | - |
| Net margin | - | -3,200.76% | -14,121.25% | -15,368.91% | -16,729.99% | - | - |
| EPS 2 | - | -0.3600 | -0.4075 | -0.4475 | -0.4750 | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 26/03/24 | 09/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | 188 | 117 | 134 | 248 |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -45.7 | -107 | -144 | -143 |
| ROE (net income / shareholders' equity) | - | - | -220% | -52.1% | -13.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | -28.40 | 3.250 | 1.880 | 1.820 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 2.09 | 2.4 | 2.85 |
| Capex / Sales | - | - | 125.81% | 27.34% | 2.99% |
| Announcement Date | 27/10/23 | 26/03/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
32.71
USD
Average target price
68.2
USD
Spread / Average Target
+108.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 2.18B | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- CGON Stock
- Financials CG Oncology, Inc.
